MDB Capital Holdings, LLC (MDBH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: while there are promising investments like eXoZymes and HeartBeam awaiting FDA approval, the company's financial performance is contingent on future revenue and financing. The Q&A highlights concerns about shareholder dilution and management's vague timelines. Although the potential for high returns exists, the lack of immediate catalysts and uncertainties around approvals and timelines suggest a neutral impact on stock price.
Key Financial Performance
Operating Expenses $5.9 million for the first three quarters of 2025, with a goal to offset these expenses through financings. The company expects a good fourth quarter to balance the year.
Equity Holdings Significant equity positions in Paulex Bio and Buda Juice, which are expected to provide substantial equity upside for shareholders.
Revenue A fair bit of revenue is expected in the fourth quarter, which will help offset operating expenses for the year.
eXoZymes Investment MDB invested $5 million in eXoZymes, a company co-founded with inventors from UCLA. The company is making progress in synthetic biology, aiming to transform pharmaceutical development.
HeartBeam Progress HeartBeam is awaiting FDA approval for a virtual cardiologist product, which could save millions of lives by providing instant 12-lead ECGs to doctors.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
eXoZymes: eXoZymes is making significant progress with its synthetic biology platform, which is expected to enable a new paradigm in pharmaceutical development. The company is also planning to spin out transformative companies in the near future.
HeartBeam: HeartBeam is on the verge of FDA approval for a product that offers a virtual cardiologist in your pocket, enabling instant 12-lead ECGs to doctors. This innovation has the potential to save millions of lives.
Microcap Market: The CEO predicts a resurgence in the Microcap market, driven by the demand for transparency and liquidity in public markets. This is expected to create opportunities for small companies to achieve higher valuations.
Operational Scaling: MDB Capital is scaling its operations to launch 3-5 companies per year, up from one every 18 months. The company has built a deep pipeline of opportunities and is improving its processes to support this growth.
Cost Efficiency: MDB Capital has reduced the cost of taking companies public to less than $0.5 million, significantly lower than the industry standard of $2 million.
Public Venture Platform: MDB Capital is positioning itself as the only real public venture platform, focusing on launching transformative companies with billion-dollar potential.
Community Engagement: The company is leveraging its community to find CEOs, board members, and investors, which is critical for scaling its operations and launching new companies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Uncertainty: The CEO highlighted the challenging market conditions and uncertainty, which have impacted the company's stock performance and created difficulties in navigating the current environment.
Stock Performance: The company's stock has significantly declined, which has caused concern among shareholders and reflects broader challenges in the small public company market.
Scaling Operations: The company faces challenges in scaling its operations from launching one company every 18 months to 3-5 launches per year, which requires significant operational and resource adjustments.
Market Perception: There is a perception that public venture might be 'dead,' which has negatively impacted investor confidence and the company's stock valuation.
Regulatory Delays: The company is experiencing delays in regulatory approvals, such as the SEC's review process, which has slowed down the launch of new companies like Buda Juice.
Economic Cyclicality: The company is highly affected by economic cycles, with investor interest and funding availability fluctuating significantly between good and bad market conditions.
Operational Costs: The company has high operating expenses of approximately $10 million annually, which it aims to offset through financings and equity positions in launched companies.
Pipeline Execution: While the company has a deep pipeline of opportunities, executing and launching these companies successfully remains a challenge, particularly in a tough market environment.
FDA Approval Delays: The company is awaiting FDA approval for HeartBeam, which is critical for its product launch and could significantly impact its success.
Undervalued Assets: The company's stock price does not reflect the value of its significant equity holdings in companies like eXoZymes and HeartBeam, as well as other assets like its clearing platform and patent law spinout.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Company Launches: MDB Capital Holdings aims to scale its operations to launch 3 to 5 companies per year, up from the historical rate of one every 18 months. The company is optimistic about achieving this target in the near future, with a strong pipeline of opportunities and late-stage negotiations for 4 to 5 companies.
Market Outlook: The company anticipates a resurgence in the microcap market, driven by the demand for transparency and liquidity in public markets. MDB Capital Holdings believes this trend will create favorable conditions for public venture investments.
Upcoming IPOs: MDB Capital Holdings plans to close two IPOs in the fourth quarter of 2025, including Paulex Bio and Buda Juice. This marks the first time the company will achieve two launches in a single quarter.
Revenue and Financial Projections: The company expects significant revenue in the fourth quarter of 2025, which will help offset operating expenses. MDB Capital Holdings aims to cover its $10 million annual operating expenses through financing activities and equity positions in launched companies.
Equity Holdings and Asset Value: MDB Capital Holdings highlights significant equity positions in companies like eXoZymes and HeartBeam, which are expected to provide substantial future value. Additionally, the company plans to spin out its patent law firm and explore opportunities in its clearing platform, both of which are considered undervalued assets.
Strategic Focus: The company remains committed to its mission of transforming early-stage ideas into public companies with billion-dollar potential. MDB Capital Holdings emphasizes its unique platform and process as key differentiators in the market.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give a little bit of your philosophy on when shareholders could expect to see a dividend, and your philosophy on eXoZymes?
A:The philosophy is to wait until the company has a developed market for the stock and broader ownership with more trading volume. Currently, the volume is low, and the focus is on ensuring the business model and execution are clear before considering distributions.
Q:Do MDB shareholders expect to retain the same percentage of ownership as eXoZymes raises funds?
A:No, shareholders will experience dilution as the company raises more capital. However, efforts are made to minimize dilution.
Q:What is MDB's role in HeartBeam's FDA approval process and funding?
A:The Board's philosophy is to wait for FDA approval before raising more money. The FDA approval process has taken longer than expected, but once approved, it will be the first 12-lead device approved by the FDA, making it easier for investors to decide on funding.
Q:Why is MDB's stock trading at a low value despite its portfolio?
A:The microcap market has been weak, leading to skepticism about MDB's ability to pick good investments. Tax loss selling and market sentiment also contribute to the low trading value.
Q:What makes you bullish on the microcap market despite challenges?
A:Profitable and growing microcap companies are trading at high valuations, making it attractive for companies to go public. There is also a lack of funding for smaller private companies, creating opportunities for public ventures.
Q:How does MDB balance deep tech investments with ventures like Buda, a juice company?
A:MDB focuses on category leaders with strong potential. Buda represents a new category in fresh juice with a moat around its business model, making it a strong public venture opportunity despite not being deep tech.
Q:How long does it typically take for IPO-ed companies to establish themselves economically?
A:It varies. Some companies perform well quickly if they capture market imagination, while others take longer. Valuation metrics depend on factors like clinical development or revenue.
Q:What is the timeline and potential for the PatentVest spinout?
A:The timeline and market value predictions are unclear, but the spinout is expected to disrupt IP law significantly by leveraging AI and the ABS platform. It focuses on patent law, a $25 billion business, and aims to improve efficiency and reduce costs.
Q:Does MDB need more robust investor relations efforts?
A:Yes, MDB acknowledges the need to communicate its story more broadly and effectively, especially in a challenging microcap environment.
Q:Why has eXoZymes taken longer to deliver results, and what is its future potential?
A:The delay is due to a pivot in strategy from fee-for-service to launching new companies with high market value potential. Two platforms with $1 billion market cap potential are being developed, and the company is positioned for success.
Q:What is the potential of Paulex, and what is the timeline for results?
A:Paulex focuses on enabling beta cell production for insulin, a significant medical breakthrough. It has a $40 million post-money valuation and could reach a multibillion-dollar valuation after Phase Ib trials, expected to start next year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or market value predictions for the PatentVest spinout and Paulex's clinical results. Additionally, the response to why eXoZymes took longer lacked detailed clarity on the pivot's execution and timeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Community Development
Conference today
Development update
Executive Officer
Factors press
Head Community
Holdings MDB
Holdings Update
Investor Relations
MDB President
Marlett Chief
Officer Co
President Head
Relations section
Today conference
Update Conference
afternoon Investor
conference host
discussion risk
mdbcom Marlett
presentation Today
presentation result
release result
replay mdbcom
result wire
section website
today Marlett
today presentation
update statement
wire afternoon
MDBH Transcript
MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript
Unknown3-31
The earnings call presents a mixed picture with potential positive catalysts like the HeartBeam FDA approval and promising partnerships, but also highlights significant risks such as macroeconomic uncertainties, execution risks, and distribution challenges. The financial health shows moderate cash burn and strategic investments, yet the unclear guidance on PatentVest's spin-out and dilution concerns for eXoZymes add uncertainty. The Q&A session reveals management's reluctance to provide concrete details, further tempering sentiment. Thus, the overall impact on stock price is expected to be neutral.
MDB Capital Holdings, LLC (MDBH) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call reveals mixed signals: while there are promising investments like eXoZymes and HeartBeam awaiting FDA approval, the company's financial performance is contingent on future revenue and financing. The Q&A highlights concerns about shareholder dilution and management's vague timelines. Although the potential for high returns exists, the lack of immediate catalysts and uncertainties around approvals and timelines suggest a neutral impact on stock price.
MDB Capital Holdings, LLC Class A common (NASDAQ:MDBH) Q4 2024 Earnings Call Transcript
Unknown4-5
The earnings call presents a mixed picture. Financial performance is strong, with revenue and net income growth, but there are concerns about delays in SEC filings and uncertainties in forward-looking statements. The deconsolidation of Invizyne simplifies financial analysis but raises compliance issues. The Q&A session revealed limited additional insights and some management evasiveness, which may affect investor confidence. Overall, the strong financial metrics are offset by operational uncertainties, leading to a neutral sentiment.
MDB Capital Holdings, LLC (MDBH) Q4 2024 Earnings Call Transcript
Unknown4-3
The earnings call summary reveals several concerns: negative market value, regulatory issues, and cash flow challenges. Despite optimistic future revenue expectations and shareholder return plans, the Q&A section highlights management's vague responses and uncertainty in regulatory environments. The lack of strong positive catalysts and the negative perception of the company's financial health contribute to a negative sentiment, likely resulting in a stock price decline of 2% to 8% over the next two weeks.
MDBH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
